Orgenesis Competitors

Delisted . USA . 
Stock . Orgenesis
ORGSDelisted Stock  USD 1.22  0.31  20.26%   
Orgenesis competes with Quoin Pharmaceuticals, Aerovate Therapeutics, Adagene, Acrivon Therapeutics,, and Rezolute; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Orgenesis competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Orgenesis to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Orgenesis competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.061.1414.86
Details
Intrinsic
Valuation
LowRealHigh
0.061.1614.88
Details
Naive
Forecast
LowNextHigh
0.010.3314.05
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.243.475.70
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Orgenesis. Your research has to be compared to or analyzed against Orgenesis' peers to derive any actionable benefits. When done correctly, Orgenesis' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Orgenesis.

Orgenesis Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Orgenesis and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Orgenesis and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Orgenesis does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ONCR
+ 0.86
TFFP
ACRV
+ 0.79
ADAG
RZLT
+ 0.71
ADAG
ACRV
+ 0.6
TFFP
RZLT
+ 0.58
ACRV
RZLT
+ 0.57
APGN
  
High negative correlations   
ANTX
- 0.84
ONCR
ANTX
- 0.82
TFFP
AVTE
- 0.66
TFFP
AVTE
- 0.51
ONCR
ANTX
- 0.33
ACRV
ANTX
- 0.32
ADAG

Risk-Adjusted Indicators

There is a big difference between Orgenesis OTC Stock performing well and Orgenesis OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Orgenesis' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Orgenesis Competitive Analysis

The better you understand Orgenesis competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Orgenesis' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Orgenesis' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ORGS TFFP ONCR QNRX APGN AVTE ADAG ACRV RZLT ANTX
 20.26 
 1.22 
Orgenesis
 59.37 
 0.07 
Tff
 14.71 
 0.04 
Oncorus
 12.31 
 0.57 
Quoin
 2.27 
 0.43 
Apexigen
 1.17 
 2.53 
Aerovate
 1.99 
 2.05 
Adagene
 0.30 
 6.71 
Acrivon
 3.78 
 4.39 
Rezolute
 0.79 
 1.26 
AN2
Market Volatility
(90 Days Market Risk)
Out of control
Abnormally volatile
Very steady
Slightly risky
Very steady
Somewhat reliable
Unstable
Somewhat reliable
Slightly risky
Moderately volatile
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Good
Very Weak
Very Weak
Very Weak
Modest
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Dangerous
About Average
Dangerous
Low
Average
Low
Low
Above Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Strong Buy
Not Available
Hold
Buy
Strong Buy
Strong Buy
Hold
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Strong Sell
Not Rated
Strong Hold
Strong Sell
Sell
Strong Sell
Strong Hold
Current Ratio
1.57
8.18
6.42
0.96
1.24
40.85
3.1
N/A
61.78
28.17
Net Asset
14.55 M
12.03 M
145.59 M
12.17 M
22.86 M
127.42 M
115.73 M
138.26 M
132.74 M
138.74 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(54.07 M)
(20.74 M)
(75.42 M)
(9.27 M)
(32.58 M)
(81.31 M)
(14.95 M)
(59.85 M)
(68.42 M)
4.9 M
Operating Margin
-16.54
-6.09
N/A
N/A
N/A
N/A
-45.35
N/A
N/A
N/A
Current Valuation
23.01 M
(2.27 M)
25.71 M
(7.04 M)
205.33 K
(15.05 M)
14.1 M
24.86 M
148.18 M
(57.3 M)
Price To Book
1.26
0.0921
0.13
0.6
2.32
0.91
1.57
1.06
2.24
0.43
Retained Earnings
(176.62 M)
(118.33 M)
(272.01 M)
(46.2 M)
(176.79 M)
(163.42 M)
(277.75 M)
(116.42 M)
(329.44 M)
(154.46 M)
Current Asset
5.29 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.21
1.32
2.85
1.89
3.62
1.0
0.58
N/A
1.19
-0.22
Number Of Employees
146
19
64
4
11
51
174
58
59
41
Shares Outstanding
4.77 M
4.44 M
26.09 M
5.05 M
24.86 M
28.91 M
44.27 M
31.14 M
57.94 M
29.88 M
Cash Flow From Operations
(14.84 M)
(16.04 M)
(61.69 M)
(7.86 M)
(30.69 M)
(56.78 M)
(28.45 M)
(42.64 M)
(57.37 M)
(53.29 M)
Total Debt
22.62 M
115.25 K
70.65 M
3.52 K
106 K
675 K
22.31 M
4.64 M
2.23 M
14.04 M
Return On Equity
-7.27
-2.14
-1.25
-1.0
-15.98
-0.82
-0.46
-0.38
-0.58
-0.69
Z Score
N/A
N/A
-4.07
N/A
38.91
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.3
-1.06
-0.32
-0.36
-0.89
-0.49
-0.2
-0.24
-0.34
-0.43
Number Of Shares Shorted
56.25 K
157.16 K
447.72 K
95.15 K
64.45 K
1.79 M
34.66 K
1.11 M
1.12 M
71.42 K
Book Value Per Share
-3.3
4.04
1.19
5.74
-0.093
2.79
1.28
5.38
2.27
4.19
Current Liabilities
14.92 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
14.55 M
12.03 M
145.59 M
12.17 M
22.86 M
127.42 M
115.73 M
138.26 M
132.74 M
138.74 M
Debt To Equity
0.64
0.011
0.72
0.47
0.054
0.008
0.15
N/A
0.001
N/A
Short Ratio
2.39
1.77
0.74
0.2
1.72
0.98
0.33
15.38
3.16
0.82
Target Price
6.0
30.0
5.0
4.5
0.64
2.33
10.54
21.56
13.0
2.67
Shares Owned By Institutions
4.54
24.37
55.29
5.88
13.54
99.98
25.54
75.97
64.24
52.31
Market Capitalization
10.07 M
288.8 K
3.15 M
3.27 M
9.57 M
73.14 M
108.46 M
208.3 M
254.37 M
37.95 M
Price To Earning
7.52
N/A
N/A
N/A
N/A
0.64
N/A
N/A
N/A
3.96
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
15.21
0.24
N/A
N/A
N/A
N/A
109.08
N/A
N/A
N/A
Net Income
(64.92 M)
(21.24 M)
(77.42 M)
(8.69 M)
(32.07 M)
(75.52 M)
(18.95 M)
(60.39 M)
(68.46 M)
(64.73 M)
Earnings Per Share
-8.0
-5.5
-5.49
-3.66
-1.71
-2.99
-0.72
-2.66
-1.27
-1.99
Shares Owned By Insiders
21.16
3.31
12.69
2.44
8.81
0.02
10.65
22.38
13.74
21.63
Revenue
530 K
733.87 K
N/A
N/A
N/A
N/A
18.11 M
N/A
N/A
N/A
Working Capital
(12.33 M)
5.16 M
27.41 M
7.7 M
4.73 M
106.59 M
81.99 M
116.39 M
119.05 M
96.46 M
Cash And Equivalents
2.3 M
13.15 M
100.24 M
2.69 M
21.62 M
151.99 M
168.04 M
N/A
150.41 M
113.39 M
Cash Per Share
0.09
0.51
3.86
0.56
1.01
6.22
3.87
N/A
3.87
5.84
Gross Profit
36.02 M
(21.21 M)
N/A
N/A
N/A
N/A
10.18 M
N/A
N/A
N/A
Day Typical Price
1.29
0.065
0.0472
0.54
0.44
2.54
2.0
6.8
4.33
1.26
Accumulation Distribution
0.29
N/A
0.37
704577.0
0.11
55312.6
3210.26
20930.13
24079.55
3538.97
Market Facilitation Index
0.45
N/A
0.022
N/A
0.05
N/A
0.0
0.0
0.0
N/A
Daily Balance Of Power
(0.69)
(9,223,372,036,855)
(0.34)
(0.40)
(0.20)
(0.16)
0.2222
0.0299
0.5333
(0.25)
Period Momentum Indicator
(0.31)
(0.1)
(0.01)
(0.08)
(0.01)
(0.03)
0.04
0.02
0.16
(0.01)
Rate Of Daily Change
0.8
0.41
0.85
0.88
0.98
0.99
1.02
1.0
1.04
0.99
Day Median Price
1.33
0.065
0.049
0.53
0.44
2.55
1.98
6.85
4.3
1.26
Price Action Indicator
(0.26)
(0.05)
(0.01)
N/A
(0.02)
(0.03)
0.09
(0.12)
0.17
(0.01)
Relative Strength Index
39.04
25.23
39.02
47.75
49.88
52.16
43.56
47.37
38.16
53.07
Coefficient Of Variation
(587.98)
(437.78)
(655.56)
2479.98
8455.47
730.86
7339.64
(3,209)
(2,192)
1412.22
Mean Deviation
7.6
8.18
8.13
5.91
5.12
2.4
3.92
2.52
2.65
2.59
Jensen Alpha
(2.03)
(3.43)
(2.10)
0.3848
0.1058
0.4749
0.071
(0.16)
(0.17)
0.3005
Total Risk Alpha
(2.25)
(3.81)
(2.52)
0.1174
(0.15)
0.3771
(0.09)
(0.23)
(0.26)
0.1919
Sortino Ratio
N/A
N/A
N/A
0.0629
0.0108
0.1883
0.0083
N/A
N/A
0.1019
Downside Variance
N/A
N/A
N/A
37.49
43.89
5.83
30.55
N/A
N/A
8.77
Standard Deviation
11.3
14.83
13.92
10.34
8.75
3.56
5.73
3.74
3.41
4.72
Kurtosis
2.31
11.7
11.31
15.26
12.89
4.63
5.63
2.19
0.1353
13.17
Potential Upside
16.9
11.11
10.0
16.07
7.89
5.58
7.34
4.83
5.54
6.34
Treynor Ratio
(0.42)
(2.64)
1.36
0.4058
(0.17)
5.91
(0.50)
(0.08)
(0.48)
0.306
Maximum Drawdown
67.37
95.77
120.67
74.46
58.79
19.11
41.45
19.02
16.29
28.89
Variance
127.61
219.91
193.82
106.99
76.64
12.65
32.78
13.96
11.66
22.25
Market Risk Adjusted Performance
(0.41)
(2.63)
1.37
0.4158
(0.16)
5.92
(0.49)
(0.07)
(0.47)
0.316
Risk Adjusted Performance
(0.13)
(0.17)
(0.11)
0.0412
0.0185
0.1162
0.0194
(0.02)
(0.03)
0.0644
Skewness
0.3316
(2.94)
0.7357
3.24
2.85
1.69
0.735
(0.65)
0.0724
3.17
Semi Deviation
N/A
N/A
N/A
5.49
5.5
2.01
5.27
N/A
N/A
2.26
Information Ratio
(0.17)
(0.23)
(0.15)
0.0372
0.0082
0.1278
0.008
(0.04)
(0.06)
0.064
Value At Risk
(20.26)
(21.20)
(21.20)
(9.59)
(11.11)
(3.86)
(8.33)
(7.21)
(5.71)
(4.72)
Expected Short fall
N/A
N/A
N/A
(9.28)
(7.45)
(3.41)
(4.26)
N/A
N/A
(4.61)
Downside Deviation
N/A
N/A
N/A
6.12
6.62
2.41
5.53
N/A
N/A
2.96
Semi Variance
N/A
N/A
N/A
30.09
30.2
4.02
27.77
N/A
N/A
5.11

Orgenesis Competition Performance Charts

Five steps to successful analysis of Orgenesis Competition

Orgenesis' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Orgenesis in relation to its competition. Orgenesis' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Orgenesis in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Orgenesis' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Orgenesis, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Orgenesis position

In addition to having Orgenesis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities ETFs Thematic Idea Now

Utilities ETFs
Utilities ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Utilities ETFs theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Consideration for investing in Orgenesis OTC Stock

If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
CEOs Directory
Screen CEOs from public companies around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY